Coronavirus: The most advanced COVID-19 vaccines: Oxford, Johnson & Johnson, Moderna…


Coronavirus Ten of them are into Phase Three

The most advanced COVID-19 vaccines.

The whole world is watching on with keen interest as scientists work to find a vaccine to halt the coronavirus pandemic.

They’re trying to produce a vaccine in record time, with 44.5 million positive cases having been recorded around the world and with 1.1 million deaths. Here comes a look at the leading vaccine programmes and how they’re doing.

As of October 19, the date of the latest data available, there are 154 projects in the pre-clinical phase and another 44 that have overcome that stage and are in the clinical phase. There are then 10 in Phase Three, the one before approval and commercialisation. Here is a look at the leading ones.

-Oxford University’s Jenner Institute (UK). This experimental vaccine isn’t only for an adequate immune response in young people, but also in the more vulnerable elderly group.

-Janssen / Johnson & Johnson (USA). In this case, they’ve announced a pause in dosing to investigate the “unexplained illness” of a participant.

-Moderna (USA). It should be known in November if their COVID-19 vaccine, named mRNA-1273, is effective. If so, an emergency request for approval will be made in December.

-Novavax (USA). They’ve found a positive immune response, although there were moderate side effects in the majority of participants.

-Sinovac (China). This vaccine could be rolled out on a large scale at the start of next year, according to this pharmaceutical company’s estimations. They believe they could manufacture 300 million doses per year.

-Sinopharm / Wuhan Institute of Biological Products (China). These are two independent projects, with Sinopharm behind them. They’re both in the final stages of clinical trials.

-BioNTech / Fosun Pharma / Pfizer (Germany / USA). The objective is to manufacture up to 100 million doses of a vaccine in what remains of this year and potentially more than 1,200 doses in 2021.

-Gamaleya Research Institute (Russia). The preliminary results from clinical trials show no adverse incidents and they claim that antibodies can be generated.

-CanSino Biological Inc. / Beijing Institute of Biotechnology (China). Following the positive signs of this project, the Chinese intellectual property office have approved the first patent for this candidate. That means it could be produced en masse shortly.

The RUTI vaccine against COVID-19, which is being developed by researchers at the Hospital Germans Trias i Pujol and manufactured by Archivel Farma, is the first Spanish vaccine to receive authorisation for an international clinical trial, which will take place in Argentina.



Source of the article

Related posts